WHO prequalifies infant malaria treatment amid systemic neglect of structural inequities in global health access

Indigenous medicinal systems, such as the use of *Artemisia annua* in traditional Chinese medicine (Qinghao) and African ethnobotany, have provided antimalarial treatments for centuries, yet are excluded from WHO’s prequalification framework. The exclusion reflects a biomedical bias that privileges synthetic drugs over plant-based remedies, despite evidence that Artemisia derivatives are effective and culturally resonant. Indigenous healers in the Amazon and Himalayas have developed multi-symptom treatments for malaria that integrate spiritual and physical healing, offering a holistic model absent in WHO’s announcement. The systemic devaluation of these systems perpetuates a cycle where local knowledge is extracted for drug development without recognition or compensation.

Malaria control has been weaponized historically, from colonial-era 'sanitation' campaigns that blamed African bodies for disease to the DDT-spraying era of the 1950s, which disrupted ecosystems without addressing root causes. The WHO’s 1955 Global Malaria Eradication Program failed due to its top-down approach, ignoring community-based solutions like bed nets and local vector control. Structural adjustment programs in the 1980s forced endemic countries to cut health budgets, reversing gains from earlier decades. The current focus on infant treatments mirrors past patterns where technological fixes (e.g., vaccines) are prioritized over systemic reforms, repeating the mistakes of the past.

In many tropical cultures, malaria is not merely a biomedical condition but a social phenomenon tied to environmental degradation, labor exploitation, and spiritual imbalance. Indigenous communities in Papua New Guinea and the Amazon view malaria as a 'punishment' or 'curse,' integrating rituals with practical prevention, yet these perspectives are dismissed as superstition. The WHO’s announcement overlooks how cultural stigma around malaria in South Asia discourages early treatment-seeking behavior, particularly for women and girls. Cross-cultural comparisons reveal that countries like Sri Lanka and Bhutan, which combine traditional medicine with modern care, have achieved lower malaria mortality rates than those relying solely on pharmaceuticals.

The prequalified treatment, artesunate-pyronaridine, meets WHO’s stringent efficacy and safety standards, but its availability is constrained by patent barriers and supply chain inefficiencies. Scientific consensus confirms that early diagnosis via rapid diagnostic tests (RDTs) reduces child mortality, yet RDTs are often inaccessible in rural areas due to cost and distribution gaps. The neglect of newborn-specific formulations reflects a research gap where pediatric drug development is deprioritized due to lower profit margins. Emerging evidence on climate-driven malaria expansion underscores the need for adaptive scientific strategies, yet this is absent from the WHO’s framing.

Artistic traditions across malaria-endemic regions have long depicted the disease through metaphor, such as the 'fever dance' in West African cultures or the 'chill of death' in Andean folklore, reflecting its cultural weight. In India, classical dance forms like Kathakali use facial expressions to convey malaria’s symptoms, embedding medical knowledge in performance. Spiritual practices, such as prayer rituals in Islamic and Hindu traditions, are often the first line of defense in communities with limited healthcare access. The WHO’s announcement ignores how art and spirituality can bridge gaps in health literacy and trust in biomedical systems.

Climate change is projected to expand malaria transmission zones by 2050, disproportionately affecting highland regions in Africa and South America, where healthcare infrastructure is weakest. The WHO’s focus on pharmaceuticals risks creating a false sense of security, as drug resistance to artesunate-pyronaridine is already emerging in Southeast Asia. Scenario modeling suggests that integrating community health workers, indigenous knowledge, and climate-adaptive vector control could reduce child mortality by 40% by 2035. The current approach lacks a long-term strategy to address the root drivers of malaria, including deforestation and urbanization.

Women in malaria-endemic regions bear the brunt of caregiving, yet their knowledge of preventive measures (e.g., mosquito-repellent plants) is excluded from global health policy. Children in conflict zones, such as South Sudan and Yemen, face the highest malaria mortality rates due to collapsed health systems, yet their stories are absent from WHO’s narrative. Indigenous communities, who have the highest malaria burdens, are rarely consulted in drug development or policy design. The framing centers WHO and pharmaceutical corporations, erasing the voices of frontline workers and affected families who could co-design solutions.